Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Needham Reiterates Buy on Hologic, Maintains $90 Price Target

Author: Benzinga Newsdesk | April 10, 2024 05:21am
Needham analyst Mike Matson reiterates Hologic (NASDAQ:HOLX) with a Buy and maintains $90 price target.

Posted In: HOLX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist